Elevance Health stock price reaches $320, higher than the $388 average analyst target

Elevance Health stock (ELV) closed at $320 last Friday, which is 30.2% lower than its 52-week high of $458.75. Despite this, on February 26, the company reaffirmed its 2026 adjusted EPS guidance of at least $25.50. This reaffirmation came in the wake of Elevance Health’s SEC filing, where it also confirmed a GAAP earnings floor of $22.30 for the full year.

The company’s management showed confidence in its financial outlook due to a deliberate portfolio repositioning strategy. This strategy saw Carelon Services experience nearly 60% growth in 2025, while CarelonRx achieved over 20% growth. These successes helped offset the impact of a decline in affiliated memberships.

Elevance Health is undergoing a transformation from being solely a health insurer to becoming a diversified health services platform. This shift is driven by Carelon’s increasing external revenue, which is gradually decoupling from the challenges faced within the health benefits segment due to enrollment declines.

CEO Gail Boudreaux emphasized on the Q4 earnings call that the company’s growth target for 2027 is at least 12% adjusted EPS growth. Management’s confidence in this outlook is further bolstered by their commitment to approximately $2.3 billion in share repurchases for 2026, indicating a belief that the current stock price of $320 presents a compelling opportunity for capital deployment.

Looking ahead, Elevance’s focus on expanding its Carelon services positions the company to compete directly in health services delivery within the next three to five years. This strategic move aims to reduce the company’s reliance on the volatile cycles of government-program enrollment.

Despite facing industry-wide cost pressures, Elevance Health’s reaffirmation of its adjusted EPS guidance for 2026 indicates that the company’s repositioning plan remains on track. While revenue is projected to be down 1.4% year-over-year in 2026, with normalized EPS expected to decline by 14.0%, Wall Street analysts maintain confidence in the company’s trajectory.

With 11 buy ratings, 3 outperforms, and 8 holds among 20 analysts, the mean price target for Elevance Health stock is $387.90, implying a potential upside of 21.2% from the current price of $320. The analyst target range spans from $332.00 to $474.00, with Medicaid margin recovery and Carelon’s external growth momentum being key factors influencing the potential outcomes.

The valuation model for ELV stock suggests a target price of $434.40 by December 2030, indicating a total return of 35.7% and an annualized return of 6.5% from the current price of $320. Despite the market pricing ELV as structurally impaired, the growth of Carelon Services in 2025 and the share repurchase commitment for 2026 demonstrate that management sees value beyond the current price.

In conclusion, Elevance Health, Inc. is seen as undervalued at $320, with analyst consensus pointing towards a potential upside and a clear path to recovery hinging on stabilization in the Medicaid sector. Monitoring key financial metrics in upcoming earnings reports will provide further insights into the company’s growth trajectory.